Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.48 |
| ▸ | FLT3 | P36888 | 3/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9290133 | 0.79 | LRRK2 (0.49) | LRRK2PIK3CDFLT3PIK3CAPIK3CB | |
| SCHEMBL7872315 | 0.79 | MTOR (0.63) | KITLRRK2MTORALOX5APFEN1 | |
| SCHEMBL20150132 | 0.79 | ALOX5AP (0.50) | LRRK2PIK3CDPIK3CAPIK3CBPI4KA | |
| SCHEMBL3744510 | 0.79 | AXL (0.51) | LRRK2PIK3CDPIK3CAPIK3CBPI4KA | |
| SCHEMBL12395307 | 0.78 | PIK3CD (0.53) | KITLRRK2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL8184158 | 0.78 | PIK3CD (0.48) | LRRK2PIK3CDFLT3MAPTGPR55 | |
| SCHEMBL20409478 | 0.78 | PIK3CD (0.48) | KITMTORPIK3CDPIK3CAMAPT | |
| SCHEMBL20037883 | 0.78 | MAPT (0.47) | LRRK2PIK3CDFLT3PIK3CAPIK3CB | |
| SCHEMBL30519697 | 0.78 | MAPT (0.47) | LRRK2PIK3CDFLT3PIK3CAPIK3CB | |
| SCHEMBL14783930 | 0.78 | GPR55 (0.52) | LRRK2PIK3CDFLT3PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230137-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2025-07-17 | — | — | US | disclosed |
| EP-3752497-B1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3752497-B1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3365335-B1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-112218857-B | P300/CBP HAT inhibitors and methods of use thereof | 星座制药公司 | 2023-11-21 | — | — | CN | disclosed |
| WO-2023066350-A1 | CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADING AGENT DEVELOPED ON THE BASIS OF LIGAND COMPOUND, AND THEIR APPLICATIONS | 标新生物医药科技(上海)有限公司 | 2023-04-27 | — | — | WO | disclosed |
| CN-110818683-B | 2-pyridine substituted urea structure small molecule compound and synthesis and application thereof | 中国科学院上海药物研究所 | 2023-04-14 | — | — | CN | disclosed |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| EP-2345328-A1 | COMPOSITION FOR AGRICULTURAL USE | Sumitomo Chemical Company, Limited (JP) | 2011-07-20 | — | — | EP | disclosed |
| EP-1784396-B1 | PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | APP, BACE1, PSEN1 | KIT 4312/4885LRRK2 649/4885MTOR 1904/4885 |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | KIT 1986/4885LRRK2 937/4885MTOR 230/4885 |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | BACE1, APP, BACE2 | KIT 4589/4885LRRK2 185/4885MTOR 1291/4885 |
| US-20250230137-A1 | P300/CBP HAT INHIBITORS | EP300, HDAC1, KAT2A | KIT 2078/4885LRRK2 909/4885MTOR 1065/4885 |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | KIT 1986/4885LRRK2 937/4885MTOR 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.